[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334769-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334769-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","developing-innovative-strategies-of-tumor-infiltrating-lymphocyte-therapy-for-tumor-treatment-review","Developing innovative strategies of tumor-infiltrating lymphocyte therapy for tumor treatment - review","","Cancer remains a leading cause of global mortality, creating strong demand for more effective oncology treatments. Adoptive transfer of tumor-infiltrating lymphocytes (TILs) is a promising adoptive cellular immunotherapy, and clinical trials have supported its safety and efficacy. Yet TIL infusion benefits only a subset of patients, limiting anti-tumor responses. This review systematically summarizes TIL-based therapy development and proposes strategies to enhance multidimensional anti-tumor capabilities, aiming to improve effectiveness and accelerate progress.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/developing-innovative-strategies-of-tumor-infiltrating-lymphocyte-therapy-for-tumor-treatment-review/334769/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/developing-innovative-strategies-of-tumor-infiltrating-lymphocyte-therapy-for-tumor-treatment-review/334769.png","ImageObject",300,407,{"name":42,"@type":43},"Aurora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is tumor-infiltrating lymphocyte (TIL) therapy still limited in many cancer patients?","Question",{"text":63,"@type":64},"Despite established safety and efficacy in clinical trials, TIL infusion can induce anti-tumor responses only in a subset of patients. The review attributes limitations to factors such as tumor antigen heterogeneity and tumor evolution within the tumor microenvironment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the basic concept of TIL-based adoptive cellular immunotherapy?",{"text":68,"@type":64},"TILs are harvested from tumor tissues, expanded in vitro, and then infused back into a patient to exert anti-tumor activity against cancerous cells.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the review focus on to improve TIL-based therapy outcomes?",{"text":72,"@type":64},"The review summarizes the developmental history of TIL-based therapy and discusses novel strategies and future directions aimed at enhancing the multidimensional anti-tumor capabilities of TILs.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334769,1790644363,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","ONCOLOGY REPORTS 51: 85, 2024  \nDeveloping innovative strategies of tumor‑infiltrating lymphocyte therapy for tumor treatment  \nZHONGJIE YU 1* , JIANHUA SHI2* , YUAN FANG3 , YI ZHAO 1 , AOTIAN XU 1 and NING LI3  \nR&D, Qingdao Sino‑cell Biomedicine Co., Ltd., Qingdao, Shandong 266000, P.R. China; Phase Ⅰ Clinical Research Center Affiliated,  \n1 2  \nLinyi Tumor Hospital, Linyi, Shandong 276000, P.R. China; 3Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China  \nReceived January 31, 2024; Accepted April 15, 2024  \nDOI: 10. 3892/or.2024.8744  \nAbstract. Cancer is the main cause of global mortality, and thus far, effective therapeutic strategies for cancer treatment are in high demand. Adoptive transfer of tumor‑infiltrating lymphocytes (TILs) represents a promising avenue in immu‑ notherapy for the management of malignancies. The clinical safety and efficacy of TIL‑based therapy have been estab‑ lished through numerous rigorous clinical trials. However, the efficacy of TIL infusion in inducing an anti‑tumor response is limited to a subset of clinical patients with cancer. Therefore, there is an urgent need to develop innovative strategies aimed at enhancing the effectiveness of TIL‑based therapy. In the present review, the developmental history of TIL‑based therapy was systematically summarized and analyzed, while also presenting a unique perspective on enhancing the multi‑dimensional anti‑tumor capabilities of TILs. The insight and conclusions presented in this review may contribute to  \nCorrespondence to: Dr Aotian Xu, R&D, Qingdao Sino‑cell Biomedicine Co. , Ltd. , 108 Yihai Road, Chengyang, Qingdao, Shandong 266000, P.R. China  \nE‑mail: xuaotian@sino‑[cellbiomed.com](cellbiomed.com)  \nDr Ning Li, Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuannanli, Chaoyang, Beijing 100021, P.R. China  \nE‑mail: [lining@cicams.ac.cn](lining@cicams.ac.cn)  \n*Contributed equally  \nAbbreviations: CAR, chimeric antigen receptor; TIL, tumor‑infiltrating lymphocyte; ZFNs, zinc finger nucleases; PD‑1, programmed cell death 1; TCR, T‑cell receptor; TRAIL, TNF‑related apoptosis‑inducing ligand; FasL, Fas ligand; CRR, complete response rate; iPSCs, induced pluripotent stem cells;  \naAPC, artificial antigen‑presenting cells; OV, oncolytic virus Key words: tumor‑infiltrating lymphocyte, adoptive cellular immunotherapy, anti‑tumor properties, gene editing  \nimproving the efficacy of TIL‑based therapy and expediting its development.  \nContents  \n1. Introduction  \n2. Relevant techniques and significant findings in the developmental trajectory of TIL‑based therapy  \n3. Molecular and cellular mechanisms underlying the function of TILs  \n4. Novel strategies for augmenting the anti‑tumor efficacy of TILs  \n5. Conclusions and future perspectives  \n1. Introduction  \nCancer is one of the leading causes of mortality, accounting for~10 million annual deaths worldwide. According to the latest report, it was estimated that annually, there were ~4,064,000 new cases and ~2,413,500 cancer‑associated deaths in China (1) . In the US, there were ~1,958,310 new cancer cases and ~609,820 cancer‑associated deaths in 2023 (2) . In addition, cancer also negatively affects a country's economic growth; the estimated global economic cost of cancer between 2020 and 2050 is $25.2 trillion (3) . Of note, the burden of cancer shows a continuously increasing trend worldwide, and as such, cancer prevention and control are becoming an ever more prominent subject. However, the efficacy of treatments with traditional therapeutic strategies is limited, and thus, there is an urgent need to develop novel approaches for cancer treatment.  \nChimeric antigen receptor (CAR)‑T‑cell therapy is a revo‑ lution","cbCaiecno4zrVKe1","https://ap.wps.com/l/cbCaiecno4zrVKe1","pdf",1797593,"English","# Contents\n## Introduction\n## Relevant techniques and significant findings in the developmental trajectory of TIL-based therapy\n## Molecular and cellular mechanisms underlying the function of TILs\n## Novel strategies for augmenting the anti-tumor efficacy of TILs\n## Conclusions and future perspectives","[{\"question\":\"Why is tumor-infiltrating lymphocyte (TIL) therapy still limited in many cancer patients?\",\"answer\":\"Despite established safety and efficacy in clinical trials, TIL infusion can induce anti-tumor responses only in a subset of patients. The review attributes limitations to factors such as tumor antigen heterogeneity and tumor evolution within the tumor microenvironment.\"},{\"question\":\"What is the basic concept of TIL-based adoptive cellular immunotherapy?\",\"answer\":\"TILs are harvested from tumor tissues, expanded in vitro, and then infused back into a patient to exert anti-tumor activity against cancerous cells.\"},{\"question\":\"What does the review focus on to improve TIL-based therapy outcomes?\",\"answer\":\"The review summarizes the developmental history of TIL-based therapy and discusses novel strategies and future directions aimed at enhancing the multidimensional anti-tumor capabilities of TILs.\"}]","Developing innovative strategies of tumor-infiltrating lymphocyte therapy for tumor treatment - review | PDF",1790008305,25]